May 28, 2020

Yttrium-90 Radioembolization Analyzed in Patients With Intrahepatic Cholangiocarcinoma

May 28, 2020—In Journal of Vascular and Interventional Radiology (JVIR), Stefan Buettner, MD, et al reported observational data of treatment outcomes of yttrium-90 (Y-90) radioembolization in patients with unresectable intrahepatic cholangiocarcinoma.

The investigators performed a retrospective review of 115 patients at six tertiary care centers. Of these patients, 92 were treated with resin microspheres (80%), 22 were treated with glass microspheres (19%), and one was treated with both. Postintervention outcomes were compared between groups with chi-square tests. Survival after diagnosis and after treatment was assessed by Kaplan-Meier method.

JVIR reported the following:

  • Grade 3 laboratory toxicity was observed in four patients (4%).
  • No difference in toxicity profile between resin and glass microspheres was observed (P = .35).
  • Clinical toxicity per Society of Interventional Radiology criteria was noted in 29 patients (25%).
  • Partial response per Response Evaluation Criteria In Solid Tumors 1.1 was noted in 25% of patients who underwent embolization with glass microspheres and 3% of patients who were treated with resin microspheres (P = .008).

The investigators found that median overall survival (OS) from first diagnosis was 29 months (95% CI, 21-37 months) for all patients. The 1-, 3-, and 5-year OS rates were 85%, 31%, and 8%, respectively. Median OS after treatment was 11 months (95% CI, 8-13 months). The 1- and 3-year OS rates were 44% and 4%, respectively.

These estimates were not significantly different between resin and glass microspheres (P = .73 and P = .475, respectively). Five patients were able to undergo curative-intent resection after Y-90 radioembolization (4%), noted the investigators in JVIR.


May 29, 2020

SCAI Survey Finds That Americans Are Avoiding Treatment for Heart Attack and Stroke Because of COVID-19 Risk

May 28, 2020

Study Confirms Stroke Patients Are Significantly Delaying Treatment During COVID-19 Pandemic